First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Ligation of glucocorticoid‐induced tumor necrosis factor receptor (GITR) decreases regulatory T cell–mediated suppression and enhances T‐cell proliferation, effector function, and survival. MK‐1248 is a humanized immunoglobulin G4 anti‐GITR monoclonal antibody agonist. Methods: In patients with advanced solid tumors, MK‐1248 (starting dose, 0.12 mg) was tested alone and with pembrolizumab (200 mg) according to a 3 + 3 dose escalation design (ClinicalTrials.gov identifier NCT02553499); both treatments were administered intravenously every 3 weeks for ≤4 and ≤35 cycles, respectively. The safety and tolerability, maximum tolerated dose, and pharmacokinetics/pharmacodynamics were explored. Results: Twenty patients received MK‐1248 monotherapy; 17 received combination therapy. The most frequent tumor types were colorectal cancer (n = 8), melanoma (n = 6), and renal cell carcinoma (n = 4). MK‐1248 was generally well tolerated at the maximum tested doses of 170 (monotherapy) and 60 mg (combination). No dose‐limiting toxicities (DLTs) or treatment‐related deaths occurred. Adverse events (AEs) occurred in 36 of the 37 patients (97%); the most common were vomiting (n = 13 [35%]), anemia (n = 10 [27%]), and decreased appetite (n = 10 [27%]). Grade 3 to 5 AEs occurred in 19 of the 37 patients (51%). Treatment‐related AEs occurred in 18 of the 37 patients (49%): 9 of the 20 patients (45%) on monotherapy and 9 of the 17 patients (53%) on combination therapy. Among the 17 patients receiving combination therapy, 1 achieved a complete response and 2 achieved a partial response, for an objective response rate of 18%; no patients achieved an objective response with monotherapy. The disease control rate (stable disease or better) was 15% with monotherapy and 41% with combination therapy. Conclusions: MK‐1248 was generally well tolerated at doses up to 170 (monotherapy) and 60 mg (combination), with no DLTs or treatment‐related deaths. Combination therapy provided limited antitumor responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Wang, B., Zhang, W., Jankovic, V., Golubov, J., Poon, P., Oswald, E. M., Gurer, C., Wei, J., Ramos, I., Wu, Q., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat7061 · Cited by 167 · cited 3×
“1-14) Partial response 0 0 (0-17) 2 12 (2-36) 2 5 (0.”
Research works printed but not linked: 23
- 10.1186/s12916-016-0623-5 · DOI · Paper page
- 10.1016/j.cell.2017.01.017 · DOI · Paper page
- 10.1016/j.ejca.2016.06.028 · DOI · Paper page
- 10.1073/pnas.94.12.6216 · DOI · Paper page
- 10.1016/S0960-9822(99)80093-1 · DOI · Paper page
- 10.1016/j.coi.2011.12.011 · DOI · Paper page
- 10.1158/0008-5472.CAN-16-1439 · DOI · Paper page
- 10.1111/j.1476-5381.2011.01753.x · DOI
- 10.4049/jimmunol.177.10.7398 · DOI · Paper page
- 10.3390/vaccines4030028 · DOI · Paper page
- 10.1002/hep.26013 · DOI · Paper page
- 10.1073/pnas.0710529105 · DOI
- 10.1007/s00262-008-0622-2 · DOI
- 10.1002/eji.200636933 · DOI
- 10.4049/jimmunol.179.9.5916 · DOI
- 10.1073/pnas.2334901100 · DOI · Paper page
- 2020, Keytruda (pembrolizumab) injection, for intravenous use
- 10.1111/cei.13264 · DOI
- 10.1186/1479-5876-12-36 · DOI · Paper page
- 10.1093/biomet/26.4.404 · DOI · Paper page
- 10.1186/s40425-018-0407-x · DOI
- Heinhuis KM, 2019, Safety, tolerability, and potential clinical activity of a glucocorticoid‐induced TNF receptor–related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors: a phase 1/2a dose‐escalation and cohort‐expansion clinical trial, JAMA Oncol, 6, 1
- 10.1038/s41591-019-0420-8 · DOI · Paper page
Cited by
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
T-cell agonists in cancer immunotherapy
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000966 · Cited by 119
Jiang, C., Zhang, L., Xu, X., Qi, M., Zhang, J., He, S., Tian, Q., & Song, S. (2021) · Advanced Science · doi:10.1002/advs.202102500 · Cited by 77
Immunotherapies targeting stimulatory pathways and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01085-3 · Cited by 52
“There was 1 patient with CR, 2 with PR and 3 patients with SD [42, 43].”
Background
Metadata
- Authors
- Geva, R., Voskoboynik, M., Dobrenkov, K., Mayawala, K., Gwo, J., Wnek, R., Chartash, E., & Long, G. V.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2020-08-18
- Volume
- 126
- Issue
- 22
- Pages
- 4926-4935
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W3055519780
- Cited by
- 66
- References
- 3
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Merck Sharp and Dohme
- Merck
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.